J&J Q1 2020 Earnings Update

On Tuesday, April 14, J&J held their Q1 ‘20 earnings call (press release / slides). While the call focused predominantly on J&J’s response to the COVID-19 crisis, the company stated that filing of JNJ-4528 (BCMA CAR-T) continues to be projected for H2 2020. J&J also emphasized their determination to reduce the impact of the pandemic on their ongoing clinical trials. Below, FENIX provides highlights and analysis from the call, including how JNJ-4528’s upcoming filing may impact BMS’s ide-cel, the current BCMA CAR-T frontrunner.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.